RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.

Acute Kidney Injury / drug therapy Animals Antineoplastic Agents / administration & dosage Cisplatin / adverse effects Humans Kidney / drug effects Male Mice Mice, Inbred C57BL Necroptosis / drug effects Oxidative Stress / drug effects Protein Kinase Inhibitors / administration & dosage Receptor-Interacting Protein Serine-Threonine Kinases / antagonists & inhibitors
RIPK1 inhibitor actue kidney injury inflammation necroptosis oxidative stress

Journal

Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731

Informations de publication

Date de publication:
31 07 2019
Historique:
received: 08 06 2019
revised: 12 07 2019
accepted: 17 07 2019
pubmed: 19 7 2019
medline: 9 4 2020
entrez: 19 7 2019
Statut: epublish

Résumé

Acute kidney injury (AKI) is a destructive clinical condition induced by multiple insults including ischemic reperfusion, nephrotoxic drugs and sepsis. It is characterized by a sudden decline in renal function, in addition to excessive inflammation, oxidative stress and programmed cell death of renal tubular epithelial cells. RIPK1-mediated necroptosis plays an important role in AKI. In the present study, we evaluated the treatment effects of Compound-71 (Cpd-71), a novel RIPK1 inhibitor, by comparing with Necrostatin-1 (Nec-1), a classic RIPK1 inhibitor, which has several drawbacks like the narrow structure-activity relationship (SAR) profile, moderate potency and non-ideal pharmacokinetic properties,

Identifiants

DOI: 10.1042/CS20190599 PMID: 31315969
pubmed: 31315969
pii: CS20190599
doi: 10.1042/CS20190599
doi:

Substances chimiques

Antineoplastic Agents 0
Protein Kinase Inhibitors 0
Receptor-Interacting Protein Serine-Threonine Kinases EC 2.7.11.1
Ripk1 protein, mouse EC 2.7.11.1
Cisplatin Q20Q21Q62J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1609-1627

Informations de copyright

© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Auteurs

Jia-Nan Wang (JN)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Ming-Ming Liu (MM)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Fang Wang (F)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Biao Wei (B)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Qin Yang (Q)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Yu-Ting Cai (YT)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.
Department of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China.

Xin Chen (X)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Xue-Qi Liu (XQ)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.
Department of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China.

Ling Jiang (L)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.
Department of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China.

Chao Li (C)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Xiao-Wei Hu (XW)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Ju-Tao Yu (JT)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Tao-Tao Ma (TT)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Juan Jin (J)

Department of Pharmacology, Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei 230032, China.

Yong-Gui Wu (YG)

Department of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei 230032, China.

Jun Li (J)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.

Xiao-Ming Meng (XM)

The Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China mengxiaoming@ahmu.edu.cn.
The Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Hefei 230032, China.
ORCID: 0000-0002-1166-561X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Insuffisance rénale › Atteinte rénale aigüe › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Eucaryotes › Animaux › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Produits chimiques inorganiques › Composés du platine › Cisplatine › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Nécroptose › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Phénomènes physiologiques › Stress physiologique › Stress oxydatif › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › RIPK1 inhibitor Cpd-71 attenuates renal...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Receptor-Interacting Protein Serine-Threonine Kinases › RIPK1 inhibitor Cpd-71 attenuates renal...